1-piperonylpiperazine has been researched along with 1-benzylpiperazine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arbo, MD; Cadenas, C; Carmo, H; de Lourdes Bastos, M; Godoy, P; Hengstler, JG; Melega, S; Rahnenführer, J; Reif, R; Rempel, E; Schug, M; Stöber, R | 1 |
| Arbo, MD; Ávila, DS; Bastos, ML; Carmo, H; Cestonaro, LV; Eifler-Lima, V; Garcia, I; Garcia, SC; Göethel, G; Peruzzi, CP; Souto, C | 1 |
2 other study(ies) available for 1-piperonylpiperazine and 1-benzylpiperazine
| Article | Year |
|---|---|
Hepatotoxicity of piperazine designer drugs: up-regulation of key enzymes of cholesterol and lipid biosynthesis.
Topics: Animals; Cell Survival; Cells, Cultured; Chemical and Drug Induced Liver Injury; Cholesterol; Designer Drugs; Enzyme Induction; Gene Expression Profiling; Hepatocytes; Inhibitory Concentration 50; Lipid Metabolism; Male; Oligonucleotide Array Sequence Analysis; Osmolar Concentration; Piperazines; Principal Component Analysis; Rats, Wistar | 2016 |
Piperazine designer drugs elicit toxicity in the alternative in vivo model Caenorhabditis elegans.
Topics: Animals; Animals, Genetically Modified; Behavior, Animal; Caenorhabditis elegans; Designer Drugs; Dopaminergic Neurons; Locomotion; Mechanotransduction, Cellular; Piperazines; Reactive Oxygen Species; Reproduction | 2020 |